While CD21 expression may not be the only ‘resistance factor’ for anti-CD19-MCC-DM1 therapy, these data should aid the selection of suitable preclinical lymphoma xenograft models for testing this ADC, with CD21− or CD21lo models being expected to show greater efficacy. This evidence concerns the gene CR2 and lymphoma.